Seattle Genetics, Inc. (NASDAQ:SGEN) Expected to Announce Earnings of -$0.37 Per Share

Brokerages expect Seattle Genetics, Inc. (NASDAQ:SGEN) to post earnings of ($0.37) per share for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for Seattle Genetics’ earnings, with the lowest EPS estimate coming in at ($0.43) and the highest estimate coming in at ($0.29). Seattle Genetics posted earnings per share of ($0.27) during the same quarter last year, which suggests a negative year-over-year growth rate of 37%. The business is scheduled to report its next quarterly earnings report on Thursday, October 24th.

According to Zacks, analysts expect that Seattle Genetics will report full year earnings of ($1.32) per share for the current year, with EPS estimates ranging from ($1.48) to ($1.03). For the next year, analysts forecast that the company will report earnings of ($0.73) per share, with EPS estimates ranging from ($1.76) to $0.08. Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Seattle Genetics.

Seattle Genetics (NASDAQ:SGEN) last released its quarterly earnings results on Tuesday, July 16th. The biotechnology company reported ($0.49) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.39) by ($0.10). Seattle Genetics had a negative return on equity of 17.16% and a negative net margin of 36.94%. The business had revenue of $218.45 million during the quarter, compared to analyst estimates of $189.76 million. During the same quarter last year, the firm posted $0.47 EPS. The company’s revenue was up 28.4% compared to the same quarter last year.

Several analysts recently weighed in on the company. Deutsche Bank assumed coverage on Seattle Genetics in a report on Thursday, July 18th. They issued a “hold” rating and a $79.00 price objective for the company. HC Wainwright reaffirmed a “buy” rating on shares of Seattle Genetics in a research note on Friday, April 26th. William Blair reaffirmed a “buy” rating on shares of Seattle Genetics in a research note on Friday, July 19th. Piper Jaffray Companies raised shares of Seattle Genetics from a “neutral” rating to an “overweight” rating and upped their price target for the stock from $64.00 to $75.00 in a research note on Wednesday, July 17th. Finally, ValuEngine raised shares of Seattle Genetics from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, July 17th. One investment analyst has rated the stock with a sell rating, five have given a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. The stock has a consensus rating of “Buy” and a consensus target price of $84.36.

Shares of NASDAQ:SGEN traded down $1.61 during trading on Thursday, hitting $78.36. The company’s stock had a trading volume of 430,799 shares, compared to its average volume of 909,863. Seattle Genetics has a fifty-two week low of $50.71 and a fifty-two week high of $84.37. The stock’s 50-day moving average price is $73.54 and its two-hundred day moving average price is $71.51. The company has a market capitalization of $12.89 billion, a PE ratio of -47.49 and a beta of 2.04.

In other Seattle Genetics news, insider Vaughn B. Himes sold 8,000 shares of the stock in a transaction on Friday, May 31st. The shares were sold at an average price of $65.94, for a total transaction of $527,520.00. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Clay B. Siegall sold 20,149 shares of the stock in a transaction on Thursday, August 8th. The stock was sold at an average price of $76.52, for a total transaction of $1,541,801.48. The disclosure for this sale can be found here. Insiders sold 82,577 shares of company stock worth $5,833,478 over the last ninety days. 33.80% of the stock is currently owned by company insiders.

A number of institutional investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its holdings in Seattle Genetics by 6.6% in the 4th quarter. Geode Capital Management LLC now owns 1,116,057 shares of the biotechnology company’s stock worth $63,196,000 after buying an additional 69,251 shares in the last quarter. Deutsche Bank AG lifted its position in Seattle Genetics by 10.3% in the fourth quarter. Deutsche Bank AG now owns 77,996 shares of the biotechnology company’s stock worth $4,417,000 after purchasing an additional 7,306 shares during the period. Flagship Harbor Advisors LLC lifted its position in Seattle Genetics by 112.9% in the first quarter. Flagship Harbor Advisors LLC now owns 660 shares of the biotechnology company’s stock worth $48,000 after purchasing an additional 350 shares during the period. Spectrum Management Group Inc. acquired a new stake in Seattle Genetics in the first quarter worth approximately $34,000. Finally, Meeder Asset Management Inc. acquired a new stake in Seattle Genetics in the first quarter worth approximately $394,000. 98.23% of the stock is currently owned by hedge funds and other institutional investors.

About Seattle Genetics

Seattle Genetics, Inc, a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally. The company markets ADCETRIS, an antibody-drug conjugate (ADC) for the treatment of patients with Hodgkin lymphoma or CD30-positive T-cell lymphomas.

Recommended Story: CBOE Russell 2000® Volatility Index

Get a free copy of the Zacks research report on Seattle Genetics (SGEN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Seattle Genetics (NASDAQ:SGEN)

Receive News & Ratings for Seattle Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seattle Genetics and related companies with MarketBeat.com's FREE daily email newsletter.